The HIV Resistance Response Database Initiative is a not-for-profit organisation with the mission of improving the clinical management of HIV infection through the application of bioinformatics to HIV drug resistance and treatment outcome data. The RDI has the following specific goals:

To be an independent repository of HIV resistance and treatment outcome data
To use bioinformatics to explore the relationships between resistance, other clinical and laboratory factors and HIV treatment outcome
To develop and make freely available a system to predict treatment response, as an aid to optimising and individualising the clinical management of HIV infection

Visit us at http://www.hivrdi.org

What are the limitations of genotyping?
1:29
What are the limitations of genotyping?
What is the current status of HIV treatment?
0:59
What is the current status of HIV treatment?
How should HIV treatment strategy change in resource-limited settings?
0:58
How should HIV treatment strategy change in resource-limited settings?
How is the Chelsea and Westminster working with the RDI?
1:01
How is the Chelsea and Westminster working with the RDI?
How is a new regimen selected in low income settings?
0:30
How is a new regimen selected in low income settings?
Is this approach applicable in resource-limited settings?
0:30
Is this approach applicable in resource-limited settings?
Does treatment sometimes fail?
0:40
Does treatment sometimes fail?
What is the RDI's concept?
1:10
What is the RDI's concept?
What are the challenges for optimising therapy in resource-limited settings?
1:50
What are the challenges for optimising therapy in resource-limited settings?
What happens when treatment fails?
1:33
What happens when treatment fails?
How is the next combination of drugs generally selected?
0:27
How is the next combination of drugs generally selected?
What do the RDI's models actually predict?
0:42
What do the RDI's models actually predict?
The RDI's approach
5:58
The RDI's approach
How much data has the RDI collected for this?
1:14
How much data has the RDI collected for this?
Can you give some practical examples of its use?
0:41
Can you give some practical examples of its use?
What about the future of treatment in resource-limited settings?
1:22
What about the future of treatment in resource-limited settings?
How are the models accessed?
0:36
How are the models accessed?
Dr. Andrew Revell - Executive Director, RDI.
19:02
Dr. Andrew Revell - Executive Director, RDI.
Who can use and benefit from the models?
1:09
Who can use and benefit from the models?
How do you see the role of the Chelsea and Westminster in the management of HIV infection developing
2:27
How do you see the role of the Chelsea and Westminster in the management of HIV infection developing
Dr. Brian Gazzard - Clinical Research Director, HIV. Chelsea and Westminster Hospital, London.
13:36
Dr. Brian Gazzard - Clinical Research Director, HIV. Chelsea and Westminster Hospital, London.
How does this compare with using a genotype to predict response to therapy?
0:49
How does this compare with using a genotype to predict response to therapy?
The Current Status of HIV treatment
5:27
The Current Status of HIV treatment
In what settings do you think the system may be of most use?
2:14
In what settings do you think the system may be of most use?
How do you see HIV treatment developing in the future?
2:27
How do you see HIV treatment developing in the future?
What information do you need to use the models?
0:54
What information do you need to use the models?
Do the models work for patients in different settings?
0:25
Do the models work for patients in different settings?
What can you do with the models?
1:17
What can you do with the models?
How accurate are the models?
0:33
How accurate are the models?
Dr. Brendan Larder - Scientific Chair, RDI
13:48
Dr. Brendan Larder - Scientific Chair, RDI